

Press release for immediate release

Genomtec receives sixth patent protecting the Company's technology for HPV-16 genetic diagnostics

Wrocław, Poland - November 19, 2021. - Genomtec S.A. "GMT," a NewConnect-listed MedTech company specializing in the development of advanced technology in the area of point-of-care (POCT) genetic diagnostics, has received patent protection from the Polish Patent Office for a primer set for the detection of Human papillomavirus-16 (HPV16), a method for detecting HPV16 infection, and an application of the primer set for detecting HPV infection.

HPV16 is one of the sexually transmitted viruses with a leading cause for cervical cancer due to persistent infections. Because of its oncogenic properties early diagnosis of HPV infection is important for prompt initiation of appropriate therapeutic procedures and further monitoring of the patient in order to reduce the risk of cancer development.

- As part of our work on Genomtec®ID, we plan to develop a diagnostics test menu for the detection of sexually transmitted diseases, including HPV, chlamydia and gonorrhoea-causing bacteria which will follow our current efforts of launching a panel for detecting respiratory diseases - the so-called 5 – plex panel. We know how important early diagnosis of sexually transmitted diseases is and the discomfort it brings to patients. Genomtec®ID is aimed to reduce this due to its point of care characteristics - said Miron Tokarski, co-founder and CEO of Genomtec SA.

Genomtec recently announced that it will accelerate its work on the commercialization of Genomtec®ID. The company also announced its intention to transfer its shares to the main market of the Warsaw Stock Exchange. To this end, on 29th October it submitted a prospectus to the Polish Financial Supervision Authority (UKNF). This week the company unveiled a demo of its solution at MEDICA- leading industry trade fair in Düsseldorf, Germany.

#####

Additional information at:

Genomtec S.A.
Magdalena Kicińska
+48 604 201 230
m.kicinska@genomtec.com

About Genomtec:

Genomtec is an innovative medical technology company dedicated to the development and commercialization of a mobile molecular diagnostics platform for detection of various infectious diseases, and also rapid laboratory diagnostic tests used, among others, in the detection of COVID-19 disease caused by the SARS-CoV-2 virus.

The company's flagship project is the Genomtec ID mobile IVD platform. The analyser is uniquely placed among Point-Of-Care (POC) products worldwide. It will allow for a quick and precise clinical molecular analysis outside the standard laboratory



setting, without the need to involve qualified laboratory personnel. The system uses microfluidic technology and the proprietary, patent protected SNAAT® isothermal technology. Appropriate design of the system enables the process to be carried out in record time, i.e. even in 15 minutes, with the diagnostic parameters equal to, and in some cases exceeding, the quality of PCR laboratory tests.

The development and manufacturing process is executed in close cooperation with international CMO (Contract Manufacturing Organization) companies. According to the assumptions of the Genomtec Management Board, the commercialization of the flagship solution will take place in the first half of 2022.

Manufacturing of Genomtec® SARS-CoV-2 EvaGreen® laboratory tests in RT-LAMP technology is based in Poland, with current EU market authorisation (CE-IVD), and product registration started in other regulatory jurisdictions outside Europe.

Genomtec was founded in 2016. Genomtec SA is headquartered in Wrocław.

More information at: www.genomtec.com